Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence.
Naeem. Muhammad M; Imran. Laiba L; Banatwala. Umm E Salma Shabbar UESS
Key Findings
- Retatrutide is a triple‑agonist incretin mimetic that targets multiple pathways involved in appetite and metabolism.
- Clinical trials reported dose‑dependent weight loss, with higher doses leading to greater reductions in body weight.
- The drug showed a favorable safety profile with mainly mild gastrointestinal side effects.
Practical Outcomes
- For biohackers, retatrutide looks promising as a future anti‑obesity option, but it’s not yet ready for self‑experimentation. Keep an eye on upcoming trial data, especially regarding optimal dosing and long‑term safety, before considering it in any personal protocol.
Summary
Retatrutide is a new drug that mimics three gut hormones and has shown strong weight‑loss results in early human studies. It appears to work better at higher doses, has a good safety record so far, and could become a powerful tool for people trying to lose fat, but more research is still needed before it can be used widely.
Abstract
Overweight and obesity have become global health challenges with increasing prevalence. Several drugs have received Food and Drug Administration approval for nonsyndromic obesity treatment, but most have limitations, including gastrointestinal side effects and limited weight loss efficacy. Retatrutide, a novel incretin mimetic agent, has shown promise in clinical trials for significant weight reduction. It has demonstrated dosage-dependent pharmacokinetics with favorable safety profiles. The primary focus of this paper is to explore retatrutide and critically assess its clinical trials to justify its use and feasibility while highlighting its shortcomings. This paper also delves into the subject of obesity and its health manifestations. It is expected that the use of retatrutide, a triple agonist, will result in significant weight loss among individuals who are obese or overweight.
Study Information
pubmed
2024
2024-02-05T00:00:00.000Z
10.1002/hsr2.1864
6
17